Skip to main content
Premium Trial:

Request an Annual Quote

Not Quite Sent

The US likely won't to meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month due to regulatory and other requirements, the Washington Post reports.

Last month, President Joe Biden announced that the US would be sharing, in addition to the already promised 60 million doses of the AstraZeneca vaccine, 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines. The US said it would be working with COVAX, the international vaccine effort, to distribute most of those vaccines.

But as the Post now reports, fewer than 10 million doses – mostly to Mexico, Canada, South Korea, and Taiwan – have been shipped. The holdup, it adds, is largely due to the legal, logistical, and regulatory requirements of both the US and recipient countries.

As the Hill notes, the Biden Administration has further announced it is allocating an additional 55 million doses to send abroad, 41 million of which will be distributed through COVAX to countries in Latin America, Asia, and Africa, and 14 million of which will be sent directly to countries including Colombia, Argentina, Haiti, Afghanistan, Pakistan, and Iraq.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.